(UroToday.com) Dr. Robert Motzer presented health-related quality of life (HRQoL) data from the phase 3 CLEAR study that evaluated the tyrosine kinase inhibitor lenvatinib in combination with either pembrolizumab or everolimus relative to sunitinib as first-line therapy advanced renal cell carcinoma (RCC). The combination of lenvatinib and pembrolizumab (len/pem) demonstrated significant improvement in overall survival, progression-free survival, and objective response rate relative to sunitinib, whereas the combination of lenvatinib and everolimus (len/eve) only demonstrated improved progression-free survival and response rate. The efficacy data are summarized in the table below.